A double-blind, randomized controlled trial on the effectiveness and safety of 15% malunggay ointment (Moringa oleifera) vs 2% mupirocin ointment in treating localized pyoderma.
- Author:
Sayo-Bondoc Catherine Anne S
;
Carpio Benedicto dL
;
Regalado-Morales Eileen
;
Lapitan-Torres Armelia
;
Yason Jasmin R.
- Publication Type:Journal Article
- Keywords: Moringa Oleifera; Localized Pyoderma
- MeSH: Human; Male; Female; Adult; Child; Ambulatory Care; Anti-bacterial Agents; Bacterial Infections; Erythema; Mupirocin; Ointments; Pain; Pruritus; Pyoderma
- From: Journal of the Philippine Dermatological Society 2016;25(1):11-18
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND: Superficial bacterial infection is among the most common reasons for dermatologic consult. Numerous published articles suggest that the dried leaf of malunggay exhibits antibacterial property.
OBJECTIVES: To compare the effectiveness and safety of 15% malunggay ointment with 2% mupirocin ointment in treating localized pyoderma.
METHODS: Sixty-three patients with localized pyoderma (?10% of total body surface area) were enrolled in this randomized, double-blind study to apply either 15% malunggay or 2% mupirocin ointment twice daily for 14 days. Clinical evaluation using the Global Assessment Score (GAS) for pruritus, pain, erythema, vesiculation, moistness and crusting were conducted at baseline and days 3, 7 and 14 of clinic visit.
RESULTS: Both malunggay and mupirocin groups showed significant decreases in GAS from baseline to days 3, 7 and 14 of treatment (p=0.000, Repeated measures, ANOVA). By days 7 and 14, median GAS of malunggay ointment was higher than mupirocin (1 vs. 0, p<0.05, Mann Whitney U Test). Cure rates were higher in the mupirocin arm comapred to the malunggay arm in Day 3 (53.13% vs. 38.71%), Day 7 (93.75% vs. 70.97%) and Day 14 (96.88% vs. 77.42%). No adverse events were noted after application of malunggay-based ointment at the end of the study period. There were no recurrence two weeks post treatment.
CONCLUSION: Patients in the mupirocin treatment arm had significantly lower global assessment scores and higher cure rates compared to those in the malunggay treatment arm.